Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 316069, 9 pages
http://dx.doi.org/10.1155/2010/316069
Research Article

Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma

1Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy
2CIR, Section of Molecular Medicine and Biotechnology, University “Campus Bio-Medico”, Via Álvaro del Portillo 21, 00128 Rome, Italy
3Bio-Ker, Scientific Park “Polaris”, Località Piscinamanna, 09010 Pula (Cagliari), Italy

Received 9 November 2009; Accepted 4 February 2010

Academic Editor: Daila S. Gridley

Copyright © 2010 Sandra Iurescia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. C. Tiwari, T. Murray et al., “Cancer statistics, 2004,” CA: A Cancer Journal for Clinicians, vol. 54, no. 1, pp. 8–29, 2004. View at Google Scholar · View at Scopus
  2. R. Houot and R. Levy, “Vaccines for lymphomas: idiotype vaccines and beyond,” Blood Reviews, vol. 23, no. 3, pp. 137–142, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. Koumarianou, P. Kountourakis, and T. Economopoulos, “Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma,” Journal of Steroid Biochemistry and Molecular Biology, vol. 109, no. 3–5, pp. 230–232, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. Rice, C. H. Ottensmeier, and F. K. Stevenson, “DNA vaccines: precision tools for activating effective immunity against cancer,” Nature Reviews Cancer, vol. 8, no. 2, pp. 108–120, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. A. Kutzler and D. B. Weiner, “DNA vaccines: ready for prime time?” Nature Reviews Genetics, vol. 9, no. 10, pp. 776–788, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. Ahlen, J. Soderholm, T. Tjelle et al., “In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells,” Journal of Immunology, vol. 179, no. 7, pp. 4741–4753, 2007. View at Google Scholar · View at Scopus
  7. S. A. Hurvitz and J. M. Timmerman, “Current status of therapeutic vaccines for non-Hodgkin's lymphoma,” Current Opinion in Oncology, vol. 17, no. 5, pp. 432–440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. S. Neelapu, S.-T. Lee, H. Qin, S.-C. Cha, A. F. Woo, and L. W. Kwak, “Therapeutic lymphoma vaccines: importance of T-cell immunity,” Expert Review of Vaccines, vol. 5, no. 3, pp. 381–394, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. F. Benvenuti, O. R. Burrone, and D. G. Efremov, “Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection,” Gene Therapy, vol. 7, no. 7, pp. 605–611, 2000. View at Google Scholar · View at Scopus
  10. A. Biragyn, K. Tani, M. C. Grimm, S. Weeks, and L. W. Kwak, “Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity,” Nature Biotechnology, vol. 17, no. 3, pp. 253–258, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. C. A. King, M. B. Spellerberg, D. Zhu et al., “DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma,” Nature Medicine, vol. 4, no. 11, pp. 1281–1286, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. B. Spellerberg, D. Zhu, A. Thompsett, C. A. King, T. J. Hamblin, and F. K. Stevenson, “DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C,” Journal of Immunology, vol. 159, no. 4, pp. 1885–1892, 1997. View at Google Scholar · View at Scopus
  13. A. D. Syrengelas, T. T. Chen, and R. Levy, “DNA immunization induces protective immunity against B-cell lymphoma,” Nature Medicine, vol. 2, no. 9, pp. 1038–1041, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Zhu, J. Rice, N. Savelyeva, and F. K. Stevenson, “DNA fusion vaccines against B-cell tumors,” Trends in Molecular Medicine, vol. 7, no. 12, pp. 566–572, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Baskar, C. B. Kobrin, and L. W. Kwaka, “Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1498–1510, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Campbell, W. Carroll, S. Kon et al., “Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits,” Journal of Immunology, vol. 139, no. 8, pp. 2825–2833, 1987. View at Google Scholar · View at Scopus
  17. L. Hansson, H. Rabbani, J. Fagerberg, A. Osterborg, and H. Mellstedt, “T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma,” Blood, vol. 101, no. 12, pp. 4930–4936, 2003. View at Google Scholar · View at Scopus
  18. A. Watanabe, E. Raz, H. Kohsaka et al., “Induction of antibodies to a κ V region by gene immunization,” Journal of Immunology, vol. 151, no. 5, pp. 2871–2876, 1993. View at Google Scholar · View at Scopus
  19. S. Y. Lim, S. Laxmanan, G. Stuart, and S. K. Ghosh, “Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine,” Cancer Detection and Prevention, vol. 25, no. 5, pp. 470–478, 2001. View at Google Scholar · View at Scopus
  20. M. Rinaldi, F. Ria, P. Parrella et al., “Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells,” Cancer Research, vol. 61, no. 4, pp. 1555–1562, 2001. View at Google Scholar · View at Scopus
  21. Y. Bergman, J. Haimovich, and F. Melchers, “An IgM-producing tumor with biochemical characteristics of a small B lymphocyte,” European Journal of Immunology, vol. 7, no. 8, pp. 574–579, 1977. View at Google Scholar · View at Scopus
  22. M. Rinaldi, D. Fioretti, S. Iurescia et al., “Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model,” Biochemical and Biophysical Research Communications, vol. 370, no. 2, pp. 279–284, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. E. M. Janssen, E. E. Lemmens, T. Wolfe, U. Christen, M. G. Von Herrath, and S. P. Schoenberger, “CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes,” Nature, vol. 421, no. 6925, pp. 852–856, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. L. H. Lund, K. Andersson, B. Zuber et al., “Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system,” Cancer Gene Therapy, vol. 10, no. 5, pp. 365–376, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. Rice, T. Elliott, S. Buchan, and F. K. Stevenson, “DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines,” Journal of Immunology, vol. 167, no. 3, pp. 1558–1565, 2001. View at Google Scholar · View at Scopus
  26. F. K. Stevenson, J. Rice, C. H. Ottensmeier, S. M. Thirdborough, and D. Zhu, “DNA fusion gene vaccines against cancer: from the laboratory to the clinic,” Immunological Reviews, vol. 199, pp. 156–180, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. Tymciu, C. Durieux-Alexandrenne, A. Wijkhuisen et al., “Enhancement of antibody responses in DNA vaccination using a vector encoding a universal T-helper cell epitope,” DNA and Cell Biology, vol. 23, no. 6, pp. 395–402, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. B. B. Williams, M. Wall, R. Y. Miao et al., “Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer,” Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1635–1645, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. D. Medaglini, A. Ciabattini, M. R. Spinosa et al., “Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice,” Vaccine, vol. 19, no. 15-16, pp. 1931–1939, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. M.-P. Lefranc, C. Pommie, M. Ruiz et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental and Comparative Immunology, vol. 27, no. 1, pp. 55–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. McMahon, E. Signori, K. E. Wells, V. M. Fazio, and D. J. Wells, “Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase—increased expression with reduced muscle damage,” Gene Therapy, vol. 8, no. 16, pp. 1264–1270, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. H.-G. Rammensee, J. Bachmann, N. P. N. Emmerich, O. A. Bachor, and S. Stevanovic, “SYFPEITHI: database for MHC ligands and peptide motifs,” Immunogenetics, vol. 50, no. 3-4, pp. 213–219, 1999. View at Google Scholar · View at Scopus
  33. P. Panina-Bordignon, A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia, “Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells,” European Journal of Immunology, vol. 19, no. 12, pp. 2237–2242, 1989. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. S. Demotz, C. Barbey, G. Corradin, A. Amoroso, and A. Lanzavecchia, “The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86,” European Journal of Immunology, vol. 23, no. 2, pp. 425–432, 1993. View at Google Scholar · View at Scopus
  35. E. A. James, J. Bui, D. Berger, L. Huston, M. Roti, and W. W. Kwok, “Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition,” International Immunology, vol. 19, no. 11, pp. 1291–1301, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. W. Chen and J. McCluskey, “Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines,” Advances in Cancer Research, vol. 95, pp. 203–247, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. I. Hakim, S. Levy, and R. Levy, “A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines,” Journal of Immunology, vol. 157, no. 12, pp. 5503–5511, 1996. View at Google Scholar · View at Scopus
  38. F. J. Hsu, C. B. Caspar, D. Czerwinski et al., “Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma—long-term results of a clinical trial,” Blood, vol. 89, no. 9, pp. 3129–3135, 1997. View at Google Scholar · View at Scopus
  39. F. J. Hsu, C. Benike, F. Fagnoni et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells,” Nature Medicine, vol. 2, no. 1, pp. 52–58, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. L. W. Kwak, M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy, “Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors,” The New England Journal of Medicine, vol. 327, no. 17, pp. 1209–1215, 1992. View at Google Scholar · View at Scopus
  41. S. S. Neelapu, S. Baskar, B. L. Gause et al., “Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen,” Clinical Cancer Research, vol. 10, no. 24, pp. 8309–8317, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. J. M. Timmerman, D. K. Czerwinski, T. A. Davis et al., “Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients,” Blood, vol. 99, no. 5, pp. 1517–1526, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Zhang, H. Zhang, and J. Zhao, “The role of CD4 T cell help for CD8 CTL activation,” Biochemical and Biophysical Research Communications, vol. 384, no. 4, pp. 405–408, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. C. M. Smith, N. S. Wilson, J. Waithman et al., “Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity,” Nature Immunology, vol. 5, no. 11, pp. 1143–1148, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. W. W. Leitner, M. C. Baker, T. L. Berenberg, M. C. Lu, J. P. Yannie, and M. C. Udey, “Enhancement of DNA tumor vaccine efficacy by gene gun mediated codelivery of threshold amounts of plasmid-encoded helper antigen,” Blood, vol. 113, no. 1, pp. 37–45, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus